✨
AI Summary & Key Takeaways
AI Insight⚡ TL;DR(Too Long; Didn't Read)
This is a unique case and may explain the increased rate of idiopathic bowel perforation among patients taking tocilizumab.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:In this article, we report a case of pneumatosis intestinalis associated with tocilizumab use.
📊
Key Findings & Data:In this article, we report a case of pneumatosis intestinalis associated with tocilizumab use.
💡
Conclusion & Impact:This is a unique case and may explain the increased rate of idiopathic bowel perforation among patients taking tocilizumab.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters
Özet
In this article, we report a case of pneumatosis intestinalis associated with tocilizumab use. This is a unique case and may explain the increased rate of idiopathic bowel perforation among patients taking tocilizumab.
🔖
Cite This Article
JACOBS, B., JAWAD, A., FATTAH, Z. (2018). Pneumatosis Intestinalis and Intestinal Perforation in a Patient Receiving Tocilizumab. art, Cilt: 33 - Sayı: 3, 372–375. https://ajindex.com/articles/158136